Moderna announces first participant dosed in a phase 1 trial of its nipah virus mrna vaccine, mrna-1215

Moderna advances global health commitment with mrna vaccine candidate against the nipah virus, a lethal pathogen with pandemic potential cambridge, ma / accesswire / july 12, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the first participant has been dosed in a phase 1 trial of its nipah virus (niv) vaccine candidate, mrna-1215, that was developed in collaboration with the vaccine research center (vrc), a division of the national institute of allergy and infectious diseases (niaid) at the national institutes of health (nih). this phase 1 dose-escalation, open-label clinical trial is the first study of mrna-1215 in healthy adults to evaluate the safety, tolerability, and immunogenicity of a niv mrna vaccine.
MRNA Ratings Summary
MRNA Quant Ranking